Cambrex Co. (NYSE:CBM) Expected to Announce Earnings of $0.47 Per Share

Wall Street brokerages predict that Cambrex Co. (NYSE:CBM) will announce earnings per share of $0.47 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Cambrex’s earnings, with the highest EPS estimate coming in at $0.53 and the lowest estimate coming in at $0.41. Cambrex reported earnings per share of $0.49 during the same quarter last year, which suggests a negative year over year growth rate of 4.1%. The firm is scheduled to issue its next earnings report on Thursday, November 14th.

On average, analysts expect that Cambrex will report full year earnings of $2.05 per share for the current year, with EPS estimates ranging from $2.02 to $2.08. For the next financial year, analysts forecast that the business will report earnings of $1.95 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Cambrex.

A number of research firms have weighed in on CBM. Zacks Investment Research downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Craig Hallum cut Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price objective for the company. in a report on Monday, August 12th. William Blair cut Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price objective for the company. in a report on Wednesday, August 7th. Finally, ValuEngine cut Cambrex from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $52.00.

Large investors have recently made changes to their positions in the business. State of Alaska Department of Revenue raised its position in shares of Cambrex by 126.0% during the third quarter. State of Alaska Department of Revenue now owns 25,879 shares of the biotechnology company’s stock worth $1,539,000 after acquiring an additional 14,426 shares during the last quarter. Waddell & Reed Financial Inc. purchased a new position in shares of Cambrex during the 2nd quarter valued at $6,945,000. Nuveen Asset Management LLC lifted its position in shares of Cambrex by 349.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 180,545 shares of the biotechnology company’s stock valued at $8,451,000 after buying an additional 140,418 shares during the last quarter. Marshall Wace LLP lifted its position in shares of Cambrex by 4,787.6% during the 2nd quarter. Marshall Wace LLP now owns 38,123 shares of the biotechnology company’s stock valued at $1,785,000 after buying an additional 37,343 shares during the last quarter. Finally, Morgan Stanley lifted its position in shares of Cambrex by 4.8% during the 2nd quarter. Morgan Stanley now owns 164,300 shares of the biotechnology company’s stock valued at $7,691,000 after buying an additional 7,452 shares during the last quarter.

CBM traded up $0.12 during midday trading on Friday, hitting $59.70. 6,817 shares of the company’s stock traded hands, compared to its average volume of 465,796. Cambrex has a one year low of $33.80 and a one year high of $61.16. The company has a market cap of $2.00 billion, a PE ratio of 21.56, a price-to-earnings-growth ratio of 4.65 and a beta of 2.19. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.44 and a quick ratio of 1.77. The stock’s fifty day simple moving average is $59.63 and its 200-day simple moving average is $47.98.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Further Reading: Average Daily Trade Volume – What You Need to Know

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.